Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM

Original Article from The New England Journal of Medicine — Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Read the full article here

Related Articles